Navigation Links
Determining Valuations in Challenging Times
Date:11/5/2008

In today's financial climate, the survival of smaller companies is often dependent on their ability to do deals successfully with larger pharmaceutical companies. The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, the latest report from PharmaVentures, provides expert guidance on critical aspects of deal-making, including valuations and royalty rate calculations.

Oxford, UK (PRWEB) November 5, 2008 -- In the current financial climate, the availability of venture capital will simply dry up, particularly for start-up biotech companies and those desperate for additional funding. This leaves many vulnerable companies with a critical need for cash, and their key to survival in the short-term will be deal-making with larger pharmaceutical and biotech companies. The market is now reacting to this depleted cash availability and so the terms of licensing deals are turning back in favour of those cash-rich pharmaceutical companies.



"For biotechs, protecting cash flow is key to survival, which means that licensing terms have become more crucial than ever before", claims Fintan Walton, CEO of PharmaVentures, a leading transactions firm. In fact, managing both financial as well as clinical risk will be vitally important according to the recently published report from PharmaVentures, The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector. "The adoption of the correct valuation models can enable companies to derive better value from their deal-making in these financially challenging times. The Report sets out to provide essential assessment through the most powerful methodologies available, selected case studies and PharmaVentures consultants' experience in deal making advisory services."

Nigel Borshell, Editor of the Report, says, "In these important times, the Report explodes some of the myths of valuations and royalty rates calculations, highlights what you should factor in to your own calculations and explains how best to generate useful royalty rate outcomes. It does this by providing key case histories, deal analysis, and opinion leader comment all relating to the quest for better more useable valuation data." A significant part of the content has been formulated by leveraging PharmaVentures' 16 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal-making.


Topics covered in the Report include:

  • Clear guidance on the best methodologies to use when calculating Valuations and Royalty Rates to assist with vital decision making
  • Opinions and advice from leading industry deal makers on how to calculate Royalty Rates
  • Contextual information - The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: "What do royalties mean in terms of value?" and "Where do royalties fit within the deal?"
  • More case studies - PharmaVentures highlights the issues and pitfalls

PharmaVentures has previously published three successful reports on royalty rates in the pharmaceutical industry. "However, this time we conducted even more extensive surveys and the 2009 Edition represents a complete rewrite", says Fintan Walton, "and, judging by the excellent response from companies worldwide, it will, in short time, become the industry standard reference on the topic". The new Royalty Rate Report is published under PharmaVentures' imprint, PharmaDeals®.

According to Fintan Walton: "This report complements PharmaVentures' insight and expertise to the industry on these issues particularly through our advisory services and our pan media offerings, PharmaDeals and PharmaTelevision."

Notes to Editors:

About PharmaVentures
PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of publishing products that include databases, analysis tools, and reports as well as PharmaTelevision, the industry's first dedicated online TV channel. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

www.pharmaventures.com
www.pharmadeals.net
www.pharmatelevision.com

About the Report
The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector.
A Report by PharmaVentures, Edited by Nigel Borshell
ISBN 978-0-9558821-3-5
Available in print and in electronic format
Table of Contents and Sample Pages
Order Form

Related Video from PharmaTelevision
http://www.pharmatelevision.com

PharmaVentures: Valuation methods and trends in licensing deals

Flash
Quicktime
Windows Media Player

For further information about the Report and other PharmaDeals databases and publications, including ordering, please contact:
Lisa Holloway
Marketing
PharmaVentures
Magdalen Centre
Oxford Science Park
Oxfordshire
OX4 4GA, UK

T: +44 (0) 1865 784 177
E: lisa.holloway@pharmaventures.com

For information about PharmaTelevision, please contact:
Deborah Harris
PharmaTelevision
Magdalen Centre
Oxford Science Park
Oxfordshire
OX4 4GA, UK
T: +44 (0)1865 784 162
E: enquiries@pharmatelevision.com

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1569194.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
2. CSHL scientists make progress in determining how the brain selectively interprets sound
3. New method proposed for determining which patients should get treatment for colorectal cancer
4. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
5. Determining genetic signature of lung tumors can help guide treatment
6. Fitness a Key Element in Determining Male Diabetics Longevity
7. PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer
8. Past Earnings Play Role in Determining SSDI Benefits
9. Norwalk virus: Cruise ship illness challenging and costly to hospitals, too
10. National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety
11. Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Determining Valuations in Challenging Times 
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology: